MD Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of 6.07% compared to Pediatrix Medical Group's net margin of 8.61%. Pediatrix Medical Group's return on equity of -12.67% beat Encompass Health's return on equity of 17.79%.

Pediatrix Medical Group has a consensus price target of $18.07, signalling upside risk potential of 35.47%. On the other hand Encompass Health has an analysts' consensus of $117.18 which suggests that it could grow by 14.69%. Given that Pediatrix Medical Group has higher upside potential than Encompass Health, analysts believe Pediatrix Medical Group is more attractive than Encompass Health.

Pediatrix Medical Group has a beta of 1.325, which suggesting that the stock is 32.466% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.77%.

Pediatrix Medical Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.65% to investors and pays a quarterly dividend of $0.17 per share. Pediatrix Medical Group pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pediatrix Medical Group quarterly revenues are $502.4M, which are smaller than Encompass Health quarterly revenues of $1.4B. Pediatrix Medical Group's net income of $30.5M is lower than Encompass Health's net income of $120.9M. Notably, Pediatrix Medical Group's price-to-earnings ratio is -- while Encompass Health's PE ratio is 22.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group is 0.55x versus 1.94x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD has a net margin of 6.07% compared to Pediatrix Medical Group's net margin of -156.54%. Pediatrix Medical Group's return on equity of -12.67% beat Kindly MD's return on equity of -201.03%.

Pediatrix Medical Group has a consensus price target of $18.07, signalling upside risk potential of 35.47%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Pediatrix Medical Group has higher upside potential than Kindly MD, analysts believe Pediatrix Medical Group is more attractive than Kindly MD.

Pediatrix Medical Group has a beta of 1.325, which suggesting that the stock is 32.466% more volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pediatrix Medical Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group pays -- of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend.

Pediatrix Medical Group quarterly revenues are $502.4M, which are larger than Kindly MD quarterly revenues of $647.9K. Pediatrix Medical Group's net income of $30.5M is higher than Kindly MD's net income of -$1M. Notably, Pediatrix Medical Group's price-to-earnings ratio is -- while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group is 0.55x versus 3.62x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 6.07% compared to Pediatrix Medical Group's net margin of -13.15%. Pediatrix Medical Group's return on equity of -12.67% beat The Oncology Institute's return on equity of -220.55%.

Pediatrix Medical Group has a consensus price target of $18.07, signalling upside risk potential of 35.47%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could grow by 11.73%. Given that Pediatrix Medical Group has higher upside potential than The Oncology Institute, analysts believe Pediatrix Medical Group is more attractive than The Oncology Institute.

Pediatrix Medical Group has a beta of 1.325, which suggesting that the stock is 32.466% more volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pediatrix Medical Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group pays -- of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend.

Pediatrix Medical Group quarterly revenues are $502.4M, which are larger than The Oncology Institute quarterly revenues of $100.3M. Pediatrix Medical Group's net income of $30.5M is higher than The Oncology Institute's net income of -$13.2M. Notably, Pediatrix Medical Group's price-to-earnings ratio is -- while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group is 0.55x versus 0.34x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 6.07% compared to Pediatrix Medical Group's net margin of 4.12%. Pediatrix Medical Group's return on equity of -12.67% beat US Physical Therapy's return on equity of 3.86%.

Pediatrix Medical Group has a consensus price target of $18.07, signalling upside risk potential of 35.47%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 56.21%. Given that US Physical Therapy has higher upside potential than Pediatrix Medical Group, analysts believe US Physical Therapy is more attractive than Pediatrix Medical Group.

Pediatrix Medical Group has a beta of 1.325, which suggesting that the stock is 32.466% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.634%.

Pediatrix Medical Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.55% to investors and pays a quarterly dividend of $0.45 per share. Pediatrix Medical Group pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

Pediatrix Medical Group quarterly revenues are $502.4M, which are larger than US Physical Therapy quarterly revenues of $180.4M. Pediatrix Medical Group's net income of $30.5M is higher than US Physical Therapy's net income of $7.4M. Notably, Pediatrix Medical Group's price-to-earnings ratio is -- while US Physical Therapy's PE ratio is 37.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group is 0.55x versus 1.56x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.